Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial

AIMS: Both left ventricular (LV) and left atrial (LA) dysfunction and remodelling contribute to adverse outcomes in heart failure with reduced ejection fraction (HFrEF). Danicamtiv is a novel, cardiac myosin activator that enhances cardiomyocyte contraction. METHODS AND RESULTS: We studied the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Voors, Adriaan A., Tamby, Jean‐François, Cleland, John G., Koren, Michael, Forgosh, Leslie B., Gupta, Dinesh, Lund, Lars H., Camacho, Albert, Karra, Ravi, Swart, Henk P., Pellicori, Pierpaolo, Wagner, Frank, Hershberger, Ray E., Prasad, Narayana, Anderson, Robert, Anto, Anu, Bell, Kaylyn, Edelberg, Jay M., Fang, Liang, Henze, Marcus, Kelly, Cynthia, Kurio, Gregory, Li, Wanying, Wells, Kate, Yang, Chun, Teichman, Sam L., del Rio, Carlos L., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2020
Materias:
TREATMENT OF HFrEF
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689751/
https://www.ncbi.nlm.nih.gov/pubmed/32558989
http://dx.doi.org/10.1002/ejhf.1933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689751/
https://www.ncbi.nlm.nih.gov/pubmed/32558989
http://dx.doi.org/10.1002/ejhf.1933

Ejemplares similares